The Filing Desk

Macrogenics

MGNX · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

MGNX · Last close · November 19, 2026
$1.98
Value Macrogenics yourself

Macrogenics' revenue fell 0.3% to $150 million in fiscal 2025. Its operating margin was −48.7%, up from −73.7% a year earlier. Free cash flow was −$83 million. The diluted share count rose 0.8%.

MACROGENICS, INC. Latest fiscal year ended December 31, 2025 10-K filed March 9, 2026 · 0001125345-26-000017 Updated
Revenue
$150M
0.3%
Operating margin
−48.7%
25.0 pts
Net income
−$75M
 
Free cash flow
−$83M
 
Return on equity
−87.0%
37.1 pts
Market cap
$126M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Macrogenics does

MacroGenics is a clinical-stage biopharmaceutical company that develops antibody-based cancer treatments. It builds its drug candidates from its own antibody technology platforms, including antibody-drug conjugates, which link an antibody to a cancer-killing drug, and multi-specific antibodies that it calls DART and TRIDENT molecules.

It has three proprietary candidates in clinical trials: lorigerlimab, MGC026 and MGC028. Three products developed with its technology have FDA approval, but it has out-licensed or sold them to partners: Zynyz, Margenza and Tzield. It keeps certain economic rights, so it can receive payments on them.

Much of its money comes from partners. Its collaborations have provided over $1.6 billion of non-dilutive funding, meaning funding that does not give up ownership. It also works with Gilead Sciences on a candidate called MGD024. It runs a commercial-scale antibody factory at its Maryland headquarters and provides contract manufacturing to partners and others to help cover the plant's costs.

Its biggest risks, as it describes them

  • It will need substantial additional funding, which may not be available on acceptable terms.
  • It has lost money since it began and may never be profitable.
  • Drug development is long and costly, and its outcome is highly uncertain.
  • Raising money could dilute owners or require it to give up rights.
From Macrogenics's annual report on Form 10-K, filed March 9, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Macrogenics lost money in fiscal 2025: a net loss of $75 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments12410910118357
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage——−117.7x−99.2x−8.6x
Current ratio3.8x4.6x4.5x3.9x5.1x
Quick ratio3.7x4.5x4.5x3.9x4.9x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Macrogenics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Macrogenics says to expect

  • Cash runwayMacroGenics anticipates that its cash, cash equivalents and marketable securities of $287.7 million as of September 30, 2026, in addition to projected and anticipated future payments from partners, will support its cash runway through 2028.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 12, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Macrogenics shares on the open market, and 1 insider sold $129,086, all of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Aug 19, 2026Jeffrey Stuart PetersSenior VP, GC, and SecretarySold plan31,105$4.15$129,086Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−197.4%107.2%−55.8%
Altman Z''−10.44−12.52−12.89
Accruals ratio23.9%0.5%2.5%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassFailFail
Cash from operations exceeds net incomeFailFailFail
Debt fell relative to assets———
Current ratio roseFailFailPass
Share count didn't riseFailFailFail
Gross margin rosePassPassPass
Revenue rose relative to assetsFailPassPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Macrogenics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
MacrogenicsFY25−0.3%−48.7%−55.5%———
Karyopharm TherapeuticsFY250.6%−62.1%−51.6%——2Compare
Beam TherapeuticsFY25120.0%−274.6%−257.6%———Compare
RegenxbioFY25104.5%−94.6%−74.2%———Compare
Valneva SEFY253.0%−47.0%−32.8%−34.5%—1Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue9215860641057715259150150
Revenue growth−8.9%71.7%−61.9%6.8%63.4%−26.2%96.2%−61.3%155.3%−0.3%
Gross profit———641057514958149150
Research and development122147191195193215207167177147
Operating income−60−22−171−177−131−203−121−168−111−73
Net income−58−20−172−152−130−202−120−9−67−75
Diluted EPS (US$)−1.69−0.54—−3.16−2.47−3.37−1.95−0.15−1.07−1.18
Diluted shares (millions)35364148526061626363
Cash flow
Cash from operations−4414−153−134−112−144−87−78−68−81
Capital expenditure1129254664242
Free cash flow−55−15−178−139−118−150−91−80−72−83
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation12151620212320182914
Balance sheet at fiscal year end
Cash and short-term investments8421222012618112410910118357
Debt incl. finance leases——————————
Total assets311374332312379335280298262257
Total liabilities427589828396138146146201
Shareholders' equity26929924323129624014215311656
Margins and ratios
Gross margin———100.0%100.0%96.6%97.8%99.0%99.4%100.0%
Operating margin−65.3%−14.0%−284.8%−276.0%−125.0%−261.9%−79.9%−286.4%−73.7%−48.7%
Net margin−63.7%−12.4%−285.2%−236.5%−123.7%−261.0%−78.8%−15.4%−44.7%−49.9%
Free cash flow margin−59.9%−9.5%−296.4%−215.9%−112.3%−193.7%−59.6%−136.1%−48.1%−55.5%
Rule of 40 (growth + FCF margin)−68.8%62.2%−358.3%−209.1%−48.9%−219.9%36.6%−197.4%107.2%−55.8%
Return on capital——————————
Return on equity−20.1%−6.9%−63.2%−64.1%−49.3%−75.5%−62.8%−6.2%−49.9%−87.0%
Return on assets−17.5%−5.7%−48.6%−47.1%−37.5%−56.6%−38.9%−3.1%−23.9%−28.8%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Macrogenics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Macrogenics.